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MaOBJECTIVES This study sought to evaluate the self-expandable ACURATE TA device (Symetis SA, Ecublens,
Switzerland) in a cohort of patients with pure aortic regurgitation (AR).
BACKGROUND Transcatheter aortic valve replacement (TAVR) has been initially considered as an alternative for high-
risk patients with aortic stenosis. Although the current experience is limited, TAVR might be also an alternative to treat
patients with pure, severe AR.
METHODS Between April 2012 and December 2013, a total of 8 high-risk patients with pure, severe AR were enrolled
(grade IIIþ). Clinical and hemodynamic data as well as data on device and procedure parameters and outcomes were
collected.
RESULTS Patient mean was 72.5  8.4 years, and 37.5% of patients were female. Logistic EuroSCORE was 34.0  7.9%
and the Society of Thoracic Surgeons score was 7.3  3.3% on average. Two patients had undergone emergency aortic
operation before due to acute type A aortic dissection, and both were treated by replacement of the ascending aorta
(including root reconstruction) and the aortic arch combined with or without E-vita Open stent graft (Jotec GmbH,
Hechingen, Germany) (January 2011 and March 2012), whereas the other patients experienced primary AR. All patients
underwent successful transapical TAVR with the transapical ACURATE TA device (size small, n ¼ 1, size medium, n ¼ 3,
size large, n ¼ 4) without any intraprocedural complications according to the Valve Academic Research Consortium
2 criteria. Post-procedure AR grade Iþ or lower, as revealed by transoesophageal echocardiography and angiography,
was present in all 8 patients. At 30 days, the stroke incidence and all-cause mortality rate were 0%.
CONCLUSIONS This small single-center series demonstrates the feasibility of transapical TAVR with the self-
expandable ACURATE TA device in high-risk patients with severe AR. (J Am Coll Cardiol Intv 2014;7:1159–67)
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ABBR EV I A T I ON S
AND ACRONYMS
AAD = acute aortic dissection
AR = aortic regurgitation
NYHA = New York Heart
Association
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiography
VARC = Valve Academic
Research Consortium
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1160transapical TAVR by the use of the self-
expandable and self-positioning ACURATE
TA (Symetis SA, Ecublens, Switzerland) THV
in a cohort of high-risk patients with pure AR.
METHODS
STUDY DESIGN. The present study was a
prospective, nonrandomized, single center
feasibility study including eight consecutive
patients, who underwent transapical TAVR
with the ACCURATE TA device at the West-
German Heart Center Essen between April
2012 and December 2013. The present study
obtained institutional review board approval
according to the Declaration of Helsinki. Onlyhigh-risk patients with a logistic EuroSCORE >20%
were enrolled in the present study. The indication for
TAVR in the individual patient was discussed for each
patient in an interdisciplinary consensus conference
(heart team) of cardiologists and cardiac surgeons,
and the patient’s or physician’s preference alone was
not considered adequate for decision making. In
addition, all patients were informed in detail about
the TAVR procedure and the off-label use of the
ACURATE TA device, and all patients gave written
informed consent.SEE PAGE 1175The primary study endpoint was in-hospital mor-
tality, deﬁned as all causes of death within 30 days,
including all enrolled patients. Follow-up was also
performed. Patient and operative demographic char-
acteristics were recorded in a prospective institu-
tional database and retrospectively extracted and
evaluated. Echocardiographic data were stored in an
institutional parallel workﬂow platform (Horizon
Cardiology, Medcon/McKESSON, San Francisco, Cali-
fornia). Chronic obstructive pulmonary disease was
deﬁned according to the EuroSCORE deﬁnition. Sur-
vival was obtained by active follow-up. All outcomes
were reported according to the standardized Valve
Academic Research Consortium (VARC 2) criteria.
ECHOCARDIOGRAPHY. Preoperative echocardio-
graphic assessment. Transthoracic echocardiography.
Preoperative transthoracic 2-dimensional echocar-
diographic standard views were obtained with pa-
tients in the left lateral supine position using a
standard ultrasound system with a 1- to 5-MHz (S5-1)
probe (iE33, Philips Medical Systems, Andover,
Massachusetts). Left ventricular dimensions were
measured according to the recommendations of the
American Society of Echocardiography. Standard
gray-scale images were obtained in the standardparasternal (long and short axis) and apical views
(2- and 4-chamber and apical long-axis views).
Doppler ﬂow data were acquired from the left
ventricular outﬂow tract region in the pulsed-wave
mode and from the aortic valve in the continuous-
wave mode in the apical 5-chamber view. In case of
atrial ﬁbrillation, a representative heartbeat was
taken.
Transesophageal echocardiography. Detailed trans-
esophageal echocardiography (TEE) was performed
before TAVR. Two-dimensional TEE was performed
with the use of a standard Philips i33 ultrasound
system with a multiplane (X7-2t) matrix-array probe
(Philips Medical Systems). The probe consists of a
transducer that provides high-resolution images and
operates at broadband frequencies ranging between
2 and 7 MHz. Pre-procedural TEE was performed
after administration of topical anesthesia of the
pharynx and application of intravenous sedation
(midazolam), after which the probe was introduced
into the esophagus. Using the short-axis view, the
opening of the insufﬁcient aortic valve was
captured, and the highest quality loops were viewed
and evaluated after acquisition as described in the
following. The aortic annulus diameter was
measured by using the 3-chamber long-axis view at
an w120 angle. The diameter was measured as the
largest possible diameter during systole using the
inner edge to inner edge as recommended (4,5).
FOLLOW-UP ECHOCARDIOGRAPHIC EXAMINATIONS.
All patients underwent a detailed pre-procedural
transthoracic echocardiography (TTE) and TEE exam-
ination as described previously. Intraoperative TEE
was performed with all patients under general anes-
thesia. Post-procedural TTE was performed during
follow-up (3 to 6 months) in all patients. An experi-
enced echocardiographer who did not attend the TAVR
procedure performed all transthoracic follow-up
evaluations. During follow-up TTE, color Doppler
echocardiography was performed after optimizing the
Nyquist limit to evaluate the presence of regurgitant
valve disease. AR was evaluated according to the cur-
rent recommendations. The degree of AR was classi-
ﬁed according to the VARC-2 criteria (6). Brieﬂy, AR
severity was assessed by the grading of an experienced
echocardiographer by integrating VARC-2 criteria.
TAVR PROCEDURE. All TAVRs were performed with
patients under general anesthesia in a dedicated
hybrid operating room offering full functionality for
cardiac catheterization, anesthesiology, and cardiac
surgery; a cardiopulmonary bypass circuit and clinical
perfusion team was kept on stand-by. Competences
of the interdisciplinary heart team, consisting of
FIGURE 1 The Self-Expandable Symetis Device
Self-expandable ACURATE TA bioprosthesis (Symetis SA,
Ecublens, Switzerland).
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1161cardiac surgeons, cardiologists, anesthesiologists,
and perfusionists, provided optimal support during
the TAVR procedure. Transapical access was per-
formed as previously described by our group (7) using
4 pledged-armed U-stitches (Prolene 3-0, MH needle).
However, in contrast to our standard TAVR protocol,
intraprocedural preparatory balloon aortic valvulo-
plasty was not performed due to the absence of aortic
calciﬁcation, and, moreover, all valve implantations
were done without rapid pacing.
DEVICE. The ACURATE TA device (Symetis SA,
Ecublens, Switzerland) consists of a self-expandable
nitinol stent, available in 3 sizes of 23 (small), 25
(medium), and 27 (large) mm, covering an aortic
annulus diameter of between 21 and 27 mm (small, 21
to 23 mm; medium, 23 to 25 mm; large, 25 to 27 mm).
This self-expandable nitinol stent acts as an
anchoring structure within the native aortic annulus,
consisting of upper and lower crowns, enabling cor-
rect valve ﬁxation in a subcoronary and supra-
annular position. Three additional stabilization
arches within the outﬂow tract are used to orient the
bioprosthesis in the ascending aorta during deploy-
ment. This unique implantation method facilitates
the self-positioning of the device within the aortic
annulus. A 3-leaﬂet porcine valve composed of 3 in-
dependent porcine noncoronary leaﬂets is ﬁxed
within the lower part of the nitinol stent. A double
polyethylene terephthalate skirt covers the inner and
outer surface of the stent body and lower crown to
reinforce the biological porcine valve and thereby
avoid any direct contact between the biologic tissue
and the metal stent struts. The valve is depicted in
Figure 1. This additional polyethylene terephthalate
skirt seals the cells of the nitinol stent frame and
guarantees impermeability of the stent at the aortic
annular level to prevent leakage. The whole system
enables a sheathless implantation (28-French equiv-
alent) via the apex of the left ventricle. The valve
prosthesis is contained within the distal section of
the delivery device. The valve is released by an
unsheathing process initiated by rotating a knob on
the proximal end of the delivery system (8). The
sequence of delivery is shown in Figure 2.
STATISTICS. Continuous and normally distributed
data were reported as mean  SD. All statistical ana-
lyses were performed using the SPSS software pack-
age, version 19.0 (IBM Corp., Armonk, New York).
RESULTS
PATIENT POPULATION. Eight consecutive patients
(3 female and 5 male) with severe AR were enrolled inthe study. Mean age was 72.5  8.4 years (range, 55 to
81 years). The mean aortic valve area was 2.1  0.4
cm2. The mean B-type natriuretic peptide level before
intervention was 760  866 pg/ml. Baseline patient
characteristics are listed in Table 1. Four patients had
undergone previous cardiac surgery. Two patients
underwent previous coronary artery bypass graft
surgery, and 2 patients underwent surgery because of
an acute type A aortic dissection (AAD). Patient #1
underwent emergency cardiac surgery due to acute
AAD on March 9, 2012, at the West-German Heart
Center Essen. In this particular patient, the aortic root
was reconstructed by partial sinus replacement ac-
cording to the method of Yacoub, and the ascending
aorta and the aortic arch were replaced by a 28-mm
Dacron graft under selective cerebral perfusion. In
addition, 12-mm and 8-mm Dacron prostheses
replaced the brachiocephalic trunk and left carotid
artery, respectively. Patient #3 also underwent
emergency aortic surgery at the West-German Heart
FIGURE 2 Delivery Sequence of the Device
(A) Intra-annular positioning of the device (blue bars indicate the annular level). (B) Anatomic correct rotation (blue arrow) of the device.
(C) Partial unsheathing and pulling of the device (blue arrow) and placement of the upper crown. (D) After correct placement of the upper
crown, the lower crown (E) is released with the valve self-aligned within the aortic annulus (F).
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1162Center Essen due to complex aortic disease with AAD
on the January 13, 2011. In this patient, the ascending
aorta was replaced by a 28-mm Dacron graft, and the
aortic arch and descending aorta were treated under
selective cerebral perfusion by a 28-mm E-vita
Open stent graft prosthesis (Jotec GmbH, Hechingen,
Germany). Moreover, due to severe AR, the aortic
root was reconstructed by using gelatin-resorcinol-
formaldehyde glue, and the noncoronary sinus was
reconstructed by the ascending Dacron graft without
any additional reinforcement. Both patients showed
only grade 0-I AR after aortic reconstruction. The
other 2 patients had elective and uneventful coronary
artery bypass graft surgery in 2006 and 2001. Mean
calculated logistic EuroSCORE of the study popula-
tion (n ¼ 8) was 34.0  7.9% (range, 24.2% to
47.9%), and all patients were in New York Heart
Association (NYHA) functional class III or IV. Figure 3
illustrates AR of patients 1 and 2 as diagnosed by pre-
procedural TEE.
Patient 7 underwent an elective cardiac catheteri-
zation in a referring hospital, resulting in cardiac
perforation with cardiac tamponade, which was
treated by echocardiography-guided percutaneous
pericardial puncture and pigtail catheter placement.
He was transferred for emergency treatment to our
department, presenting with cardiac tamponade
requiring inotropic support.PROCEDURE RESULTS. TAVR was technically suc-
cessful in all patients with no intraprocedural
complications. No proximal or distal valve emboli-
zation occurred. The small size device was used in
1 patient, the medium size device in 3 patients,
and the large size device in the remaining patients.
Using rapid pacing, post-dilation was performed in
2 patients. The ﬁnal angiographic examination
showed no signs of AR or coronary obstruction
by the stent frame itself. Figure 4 illustrates the
intraoperative angiographic results of patients 1
and 2.
The 30-day all-cause mortality rate was 0%, and
no major stroke occurred in any patient. At 3 to 6
months follow-up, all patients were alive without
any major adverse events. No permanent pacemaker
implantation was needed. One patient experienced
gastrointestinal bleeding due to dual-antiplatelet
therapy, which was treated conservatively. As of
January 10, 2014, all patients were contacted by
active telephone follow-up with no adverse events
reported. Procedural and postoperative characteris-
tics are shown in Table 2, and clinical and safety
outcomes according to VARC-2 in Table 3. No
myocardial infarction occurred with maximal car-
diac troponin I levels of 6.26  2.74 ng/ml 24 h
postoperatively. At 3- to 6-month follow-up, only
Patient #1 showed trace paravalvular leakage.
TABLE 1 Demographic Characteristics
Patient #
Age,
yrs
Male,
n.
NYHA Functional
Class
Log ES I,
%
STS Score,
% Comorbidities Etiology of AR
Crea,
mg/dl
BNP,
pg/ml COPD AR MR TR
LVEF,
%
1 68 1 III 31.8 4.2 Previous aortic surgery, systemic
hypertension, neurological
dysfunction
Secondary AR after failed
aortic root repair
1.2 198.3 0 III-IV 2 1 55
2 73 0 III 41.3 5.4 CABG surgery 2006, diabetes,
previous multiple PCIs,
systemic hypertension, obesity,
severe COPD (FEV1, 53.4%,
steroids, long-term use of
bronchodilators)
Sclerotic-degenerative 1.1 124.0 1 IV 1 1 50
3 55 1 III 24.2 11.4 Previous aortic surgery with
persisting aortic type B
dissection, severe COPD
(FEV1, 47.5%, long-term
use of bronchodilators),
renal insufﬁciency,
systemic hypertension
Secondary AR after failed
aortic root repair
2.1 976.8 1 III-IV 1 1 53
4 71 1 III 32.3 6.6 CABG surgery 2001, dialysis,
systemic hypertension
Sclerotic-degenerative 8.6 — 0 IV 2 1 50
5 74 0 III 47.9 5.9 Previous PCI, systemic hypertension,
atrial ﬁbrillation,
peripheral artery disease, obesity
Sclerotic-degenerative 1.6 395 0 IV 1 1 49
6 77 1 IV 29.9 6.7 Severe COPD (FEV1 51.2%, long-term
use of bronchodilators), renal
insufﬁciency, previous
PCI, systemic hypertension,
atrial ﬁbrillation
Sclerotic-degenerative 2.0 275.7 1 IV 3 2 45
7 81 1 III 24.5 8.9 Emergency TAVR with preoperative
inotropes, previous PCI, cardiac
tamponade due to catheterization
Sclerotic-degenerative 1.7 — 0 IV 2 2 42
8 81 0 IV 40.25 14.1 Previous PCI, cardiac
decompensation
Sclerotic-degenerative 1.3 2,595.7 0 IV 2 2 25
Mean
72.5  8.4
Mean
34.0  7.9
Mean
7.9  3.4
Mean
2.45  2.5
Mean
760  866
AR ¼ aortic regurgitation; BNP ¼ B-type natriuretic peptide; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; Crea ¼ creatinine; FEV1 ¼ forced expiratory volume; log ES I ¼ logistic EuroSCORE I; LVEF ¼ left ventricular ejection
fraction; MR ¼ mitral regurgitation; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; Pt ¼ patient; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement; TR ¼ tricuspid regurgitation.
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FIGURE 3 Pre-Operative Transesophageal Echocardiography
(A) Long-axis view of aortic regurgitation including the Doppler jet of Patient #1 and the corresponding short-axis view (B) indicating a
noncalciﬁc aortic valve disease. (C) Long-axis view of aortic regurgitation including the Doppler jet of Patient #2 and the corresponding
short-axis view (D) indicating a noncalciﬁc aortic valve disease.
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1164Figure 5 illustrates follow-up TTE of Patients 1 and
2. Mean transvalvular pressure gradients were
10.5  2.7 mm Hg with an aortic valve area of 2.0 
0.7 cm2. Patients #1, #2, #4, #6, and #7 were in
NYHA functional class I, and Patients 3, 5, and 8 inFIGURE 4 Intraprocedural Angiographic Control
Intraprocedural angiographic control after ﬁnal deployment and guidewNYHA functional class II. Left ventricular ejection
fraction did not differ between the preoperative and
3- to 6-month follow-up echocardiography (46.1 
9.5% vs. 45.6  9.1%, p ¼ 0.91). Table 4 shows the
3- to 6-month echocardiographic follow-up.ire removal in Patient #1 (A) and Patient #2 (B).
TABLE 2 Procedural and Postoperative Characteristics
Patient #
Valve
Size
Annulus
Size (TEE),
mm
Procedure
Time,
min
Contrast
Media,
ml
Fluoroscopy
Time,
min:s
Post-
Dilation Adverse Events
Second
Valve
ICU Stay,
days
RBC
Transfusion,
units
Hospital
Stay,
days
1 L 27 119 145 5:02 0 — 0 1 0 7
2 S 21 121 120 6:03 1 — 0 1 0 7
3 L 24 148 380 13:44 0 Prolonged ventilation, electrical
cardioversion due to atrial arrhythmia,
wound healing disorder
0 5 0 25
4 L 26 94 160 3:18 0 Pneumonia requiring antibiotic therapy 0 1 0 6
5 M 22 97 166 3:54 0 Pneumonia requiring antibiotic therapy,
acute renal failure requiring diuretics,
short period of AV block requiring
external pacing
0 2 0 10
6 M 21 136 100 8:37 0 — 0 1 0 6
7 L 27–28 254 300 13:35 1 Simultaneous PCI during TAVR,
postoperative delirium
0 10 0 10
8 M 21 80 130 3:11 0 — 0 2 0 6
AV ¼ atrioventricular; ICU ¼ intensive care unit; L ¼ large; M ¼ medium; RBC ¼ red blood cell; S ¼ small; TEE ¼ transesophageal echocardiography; other abbreviations as in Table 1.
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1165DISCUSSION
The present study demonstrates the ﬁrst clinical
experience and proves the feasibility of TAVR with
the ACURATE TA device in high-risk patients pre-
senting with severe AR. At present, the ACURATE TA
device is only available for implantation via the
transapical approach and has obtained the CE Mark
approval in 2011 for the treatment of stenosed and
calciﬁed aortic valve disease. A transfemoral version,
the ACURATE TF is currently in clinical trials (9).
To date, TAVR has been suggested as an alternative
treatment option to conventional aortic valve
replacement in selected patients and has become aTABLE 3 Clinical and Safety Outcomes According to VARC-2
Mortality
30-day all cause 0 (0)
30-day cardiovascular 0 (0)
12-month all cause 0 (0)
12-month cardiovascular 0 (0)
Stroke/TIA 30-day 0 (0)
Minor bleeding 0 (0)
Major bleeding 0 (0)
Blood transfusion 0 (0)
Acute kidney injury 1 (20.0)
Pacemaker implantation 0 (0)
Myocardial infarction 0 (0)
VARC-2 procedure success 8 (100)
Access site complications
Major 0 (0)
Minor 0 (0)
Values are n (%).
TIA ¼ transient ischemic attack; VARC ¼ Valve Academic Research Consortium.more widely practiced and accepted therapeutic op-
tion (1,2). TAVR was primarily developed for patients
presenting with aortic valve stenosis; however,
although aortic stenosis is more prevalent, high-risk
patients presenting with AR may beneﬁt from such
new catheter-based techniques. Therefore, we sought
to evaluate the self-expandable Symetis ACURATE TA
device in a cohort of high-risk patients with AR.
Moreover, the decision to evaluate the Symetis
ACURATE TA device in AR was mainly driven by the
fact that 2 patients presented with severe AR after
complex aortic surgery due to previous AAD. Hence,
a persisting dissection in the descending aorta
prohibited a transfemoral approach with the use of
the CoreValve prosthesis (Medtronic, Minneapolis,
Minnesota). In addition, according to our initial ani-
mal experiments, we provided evidence for safely
anchoring the Symetis ACURATE TA device in non-
calciﬁed aortic annuli (8).
The concept of TAVR was originally based on the
concept of valve ﬁxation by displacing the native
calciﬁed valve by an oversized THV. Absence of aortic
calciﬁcation may result in prosthesis dislodgement.
There are currently 2 types of transcatheter valve
available: self-expandable and balloon-expandable
THVs. The original concept of TAVR was based on
balloon-expandable valves, which depend on aortic
calciﬁcation. In contrast, self-expandable valves offer
high and permanent recoil forces, and, therefore, this
concept is better suited for treating AR. As a result,
during the past 12 months, the ﬁrst reports treating
AR only by self-expandable THVs have been pub-
lished (10–12). In addition to some single case reports,
2 larger series were reported: Roy et al. (13) presented
their results of a voluntary multi-institutional
FIGURE 5 Transthoracic Follow-up Echocardiography
(A) Patient #1 with the red arrow indicating a mild paravalvular leakage. (B) Results for Patient #2.
TABLE 4 3- to 6-Mo
Patient #
LV Functi
%
1 55
2 40
3 55
4 40
5 50
6 55
7 35
8 35
*DLVEF compares the preo
(a negative value indicates
AR ¼ aortic regurgitation
Vmax ¼ maximum velocity.
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1166registry using the self-expandable CoreValve pros-
thesis (Medtronic) in a total of 43 patients with AR. In
this series, ﬁnal implantation was performed in 42
patients (1 conversion to open heart surgery) with a
VARC-deﬁned procedure success for TAVR of 74.4%
when grade II or higher AR and the need for a second
valve were taken into account. In their series, a total
of 8 patients (18.6%) required a second valve during
the index procedure due to residual AR. Another
study by Seiffert et al. (14) evaluated a second-
generation TAVR device in a series of 5 patients
(mean age, 66.6  7.0 years) with noncalciﬁc AR. The
authors selected the JenaValve prosthesis (JenaValve
Technology GmbH, Munich, Germany) because it
features a unique clip ﬁxation mechanism of the
native aortic valve leaﬂets that may even offer secure
anchorage even in the absence of calciﬁcations. Theynth Echocardiographic Follow-Up
on,
DLVEF*
Pre-Operative vs.
3-6 Months, %
Pmax,
mm Hg
Pmean,
mm Hg
AVA,
cm2
Vmax,
m/s AR
0 16 9 1.9 2.0 I
10 15 9 1.4 1.9 0
þ2 18 10 1.5 2.1 0
10 19 11 1.6 1.6 0
þ1 28 17 N/A 2.1 0
þ10 14 9 2.2 1.9 0
7 15 9 1.8 1.9 0
þ10 18 10 N/A 1.6 0
perative left ventricular ejection fraction (LVEF) with that at 3- to 6-month follow-up
a decrease, whereas a positive indicates an increase in LVEF).
; AVA ¼ aortic valve area; LV ¼ left ventricular; N/A ¼ not available; P ¼ pressure;reported successful implantation of the device in all
cases without any major device- or procedure-related
adverse events. All patients were reported to be alive
at 3-month follow-up without any signiﬁcant AR (14).
Meanwhile, as of September 2013, JenaValve tech-
nology has received extended CE mark approval for
AR. The JenaValve is now the only TAVR device
approved for the treatment of high-risk or inoperable
patients with severe AR. The concepts of valve ﬁxa-
tion of the JenaValve and Symetis ACURATE TA
device are different because the JenaValve device
features 3 nitinol feelers. These feelers aim to embrace
the native leaﬂets of the aortic valve, irrespective
whether the leaﬂets are calciﬁed. In contrast to the
JenaValve, the Symetis ACURATE TA device offers
the difference that the 3 leaﬂets are not clipped be-
tween feelers. The self-expandable Symetis ACURATE
TA device is ﬁxed in a waistlike manner, thereby
covering the aortic annulus (hourglass design).
The decision to evaluate the ACURATE TA device
to treat AR was based on the fact that the ACURATE
TA system offers tactile feedback and comes with the
unique feature of self-positioning at a supra-annular
level (15). According to the delivery sequence of the
ACURATE TA device, the upper crown of the stent is
released and the whole prosthesis is pulled back to
reach the annular level. The lower part of the stent
crown is released only when the upper crown is in the
proper position. The tactile feedback (movement of
the whole delivery device once the aortic annulus
level is reached) guides the operator for optimal
deployment. We did not observe any valve dislodg-
ments or malpositioning. In addition, the ACURATE
TA device offers a partial resheathing of the valve
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1167until the safety knob is released. We oversized the
valve by at least 1 to 2 mm. In the present study, we
implanted mainly large valves (50%) and 3 medium-
size valves. Moreover, the patients who received a
medium-size valve showed an aortic annulus of 21 to
22 mm. This is in contrast to the manufacturer’s
recommendation in aortic stenosis that the medium
size valve cover an aortic annulus diameter of 23 to 25
mm. On the other hand, based on the unique mech-
anism of valve ﬁxation (waistlike shape) of the
Symetis device, slightly larger aortic annuli might be
treated. We were able to implant a large device in an
aortic annulus of 27 to 28 mm. VARC-2 deﬁned pro-
cedure success rate of 100%. The mean pressure
gradient (12.4  6.4 mm Hg) and aortic valve area
(2.0  0.3 cm2) were found at 6-month follow-up.
STUDY STRENGTHS AND LIMITATIONS. Our study is
the ﬁrst to evaluate the self-expandable and self-
positioning ACURATE TA prosthesis in a series of pa-
tients with AR. Despite the small number of patients
and the off-label use of the ACURATE TA device, we
observed favorable hemodynamic outcomes and nosigniﬁcant paravalvular leakages. Nevertheless, our
analysis should be viewed in the light of its limita-
tions. This single-center descriptive study is limited
by the small study numbers and therefore needs to be
conﬁrmed in a larger patient population.
CONCLUSIONS
This initial trial with the self-expandable and self-
positioning ACURATE TA device demonstrated the
feasibility of the treatment of AR. The valve hemo-
dynamic ﬁndings were satisfactory and comparable to
conventional heart valves. Furthermore, the speciﬁc
architecture of the bioprosthesis lends itself to secure
annular placement and alignment in the native
anatomy of the noncalciﬁed aortic valve.
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